Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00315393 |
Recruitment Status
:
Recruiting
First Posted
: April 18, 2006
Last Update Posted
: April 25, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Granulomatosis With Polyangiitis Microscopic Polyangiitis Wegener's |
GPA and MPA are two autoimmune disorders that cause systemic vasculitis. GPA commonly affects the upper respiratory tract, the lungs, and the kidneys. MPA is marked by kidney inflammation, weight loss, skin lesions, nerve damage, and fever. Many patients with WG or MPA show no visible symptoms of active disease; it is known that underlying subclinical disease activity leads to long-term damage in these patients. Also, because it is difficult to monitor WG and MPA disease activity, it is difficult for clinicians to know when and how to treat these patients. This study will use new scientific methods to identify new biomarkers that can be used to monitor disease activity in GPA and MPA patients. These biomarkers may be used to help direct clinical care for GPA and MPA patients and assist in future drug development.
Study visits will occur monthly for the first year, then every 3 months thereafter for the remainder of the study. Blood and urine collection will occur at every visit. A physical exam and medical and medication history will occur every 3 months; also, participants will be asked to complete several questionnaires to assess disease activity, health status, and tobacco, alcohol, and drug use. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.
Study Type : | Observational |
Estimated Enrollment : | 1200 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Determining Disease Activity Biomarkers in Individuals With Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis |
Study Start Date : | April 2006 |
Estimated Primary Completion Date : | April 2019 |
Estimated Study Completion Date : | April 2019 |

- Discover biomarkers in GPA/MPA capable of measuring disease activity and response to treatment. [ Time Frame: Study completion ]
- Measure the predictive value of biomarkers for clinical outcome in GPA/MPA [ Time Frame: Study completion. ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to classification criteria or definitions, have not been developed for GPA and MPA.
-
For diagnosis of GPA, meets at least 2 of the following 5 modified American College of Rheumatology (ACR) criteria:
- Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood
- Abnormal chest radiograph with nodules, fixed infiltrates, or cavities
- Urinary sediment with microhematuria or red cell casts
- Granulomatous inflammation within the wall of an artery or in the perivascular area on biopsy
- Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA
-
For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA:
- Necrotizing vasculitis, with few or no immune deposits, that affects small vessels (i.e., capillaries, venules, arterioles)
- Necrotizing arteritis involving small- and medium-sized arteries may be present
- Necrotizing glomerulonephritis is very common
- Pulmonary capillaritis often occurs
- Parent or guardian willing to provide informed consent, if applicable
Exclusion Criteria:
- Simultaneous diagnoses of both GPA and MPA
- Granulomatosis with polyangiitis (Churg-Strauss)
- Takayasu's arteritis
- Giant cell arteritis
- Polyarteritis nodosa
- Cogan's syndrome
- Behcet's disease
- Sarcoidosis
- Kawasaki disease
- Tuberculosis or any atypical mycobacterial infections
- Deep fungal infections
- Lymphoma, lymphomatoid granulomatosis, or any other type of cancer that mimics anti-neutrophil cytoplasmic antibody-associated vasculitis (AAVs)
- Cryoglobulinemic vasculitis
- Systemic lupus erythematosus
- Rheumatoid arthritis
- Mixed connective tissue disease or any overlapping autoimmune syndrome

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00315393
United States, Massachusetts | |
Boston University School of Medicine | Recruiting |
Boston, Massachusetts, United States, 02118 | |
Contact: Naomi Amudala, NP 617-414-2512 namudala@bu.edu | |
Principal Investigator: Paul A. Monach, MD, PhD | |
United States, Minnesota | |
Mayo Clinic | Recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Sam Hughes Hughes.Samantha@mayo.edu | |
Principal Investigator: Ulrich Specks, MD | |
Principal Investigator: Steven R. Ytterberg, MD | |
United States, Ohio | |
Cleveland Clinic Foundation | Recruiting |
Cleveland, Ohio, United States, 44195 | |
Contact: Elizabeth Kisela kiselae@ccf.org | |
Principal Investigator: Carol A. Langford, MD, MHS | |
United States, Pennsylvania | |
University of Pennsylvania | Recruiting |
Philadelphia, Pennsylvania, United States, 19104 | |
Contact: B.Minal Hatwar Bhagyavati.Hatwar@uphs.upenn.edu | |
Principal Investigator: Peter Merkel, MD, MPH | |
University of Pittsburgh | Recruiting |
Pittsburgh, Pennsylvania, United States, 15260 | |
Contact: Laurie Hope hopelk@upmc.edu | |
Principal Investigator: Larry Moreland, MD | |
United States, Utah | |
University of Utah | Recruiting |
Salt Lake City, Utah, United States, 84112 | |
Contact: Jessica Gonzalez jessica.gonzalez@hsc.utah.edu | |
Principal Investigator: Curry Koening, MD, MHS | |
Canada, Ontario | |
St. Joseph's Healthcare | Recruiting |
Hamilton, Ontario, Canada | |
Contact: Sandra Messier 905-522-1155 ext 35873 smessier@stjoes.ca | |
Principal Investigator: Nader A. Khalidi, MD | |
Mount Sinai Hospital | Recruiting |
Toronto, Ontario, Canada, M5T 3L9 | |
Contact: Judy Vendramini judy.vendramini@sinaihealthsystem.ca | |
Principal Investigator: Simon Carette, MD |
Study Chair: | Peter A. Merkel, MD, MPH | University of Pennsylvania |
Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Peter Merkel, Professor, University of Pennsylvania |
ClinicalTrials.gov Identifier: | NCT00315393 History of Changes |
Other Study ID Numbers: |
VCRC5505 U54AR057319 ( U.S. NIH Grant/Contract ) |
First Posted: | April 18, 2006 Key Record Dates |
Last Update Posted: | April 25, 2018 |
Last Verified: | April 2018 |
Keywords provided by Peter Merkel, University of Pennsylvania:
GPA MPA WG |
Additional relevant MeSH terms:
Granulomatosis with Polyangiitis Systemic Vasculitis Microscopic Polyangiitis Vasculitis Vascular Diseases Cardiovascular Diseases Lung Diseases, Interstitial Lung Diseases Respiratory Tract Diseases |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Autoimmune Diseases Immune System Diseases Cerebral Small Vessel Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases |